依鲁替尼；936563-96-1；Ibrutinib 新品

产品描述

CAS号：936563-96-1

分子式：C25H24N6O2

分子量：440.5

EINECS号：805-642-2

产品用途

依鲁替尼是布鲁顿酪氨酸激酶（BTK）抑制剂，用于治疗慢性淋巴细胞白血病（CLL）和套细胞淋巴瘤（MCL）。MCL和CLL均属于B细胞非霍奇金淋巴瘤，具有难治愈性和易复发性，常用的化学免疫疗法不具备靶向性，常发生3或4级不良反应。依鲁替尼可与B淋巴细胞形成、分化、信息传递和生存所必需的BTK靶向性结合，不可逆地抑制BTK的活性，有效抑制肿瘤细胞的增殖和存活；且口服后吸收迅速，1～2h达最大血药浓度，不良反应属于1或2级，将成为治疗CLL和MCL的新选择。

联系方式

四川青木制药有限公司

四川省眉山市东坡区经济开发区东区顺江大道南段55号

国际营销部(International):

Email: sales@eastonpharma.cn 

Tel: 028-87827187

国内营销部(Mainland)：

李经理 13880480517   

杨经理 15982276454

Product Description

CAS number: 936563-96-1

Molecular formula: C25H24N6O2

Molecular weight: 440.5

EINECS number: 805-642-2

Applications 

Ibrutinib is a Bruton tyrosine kinase (BTK) inhibitor for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Both MCL and CLL belong to B-cell non-Hodgkin lymphoma, which is difficult to cure and easy to relapse, and the commonly used chemical immunotherapy is not targeted, and often occurs grade 3 or 4 adverse reactions.Ibrutinib can bind to BTK targeting, which is necessary for the formation, differentiation, information transmission and survival of B lymphocytes, irreversibly inhibit the activity of BTK, and effectively inhibit the proliferation and survival of tumor cells. After oral absorption is rapid, the maximum blood concentration can be reached in 1 to 2 hours, and the adverse reactions belong to grade 1 or 2, which will become a new choice for the treatment of CLL and MCL.

Contact Information

Sichuan Qingmu Pharmaceutical Co., Ltd.

Add: No. 55, South Shunjiang Avenue, East Economic Development Zone, Dongpo District, Meishan City, Sichuan, 620036, China

International Marketing Department: 

Email: sales@eastonpharma.cn 

Tel: 0086-28-87827187